AngioDynamics (NASDAQ:ANGO) Stock Rating Reaffirmed by HC Wainwright

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $14.00 price objective on the medical instruments supplier’s stock. HC Wainwright’s target price would suggest a potential upside of 128.76% from the company’s previous close.

Separately, Oppenheimer upgraded AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research report on Friday, April 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

AngioDynamics Trading Down 3.2 %

Shares of NASDAQ ANGO opened at $6.12 on Wednesday. The business has a 50-day moving average of $6.05 and a 200-day moving average of $6.34. The firm has a market capitalization of $245.17 million, a price-to-earnings ratio of -1.26 and a beta of 0.67. AngioDynamics has a 12 month low of $5.26 and a 12 month high of $11.38.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 4th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). AngioDynamics had a negative net margin of 60.21% and a negative return on equity of 3.48%. On average, analysts predict that AngioDynamics will post -0.57 earnings per share for the current year.

Insider Activity

In other news, CEO James C. Clemmer bought 10,000 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was bought at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the completion of the acquisition, the chief executive officer now owns 539,066 shares in the company, valued at approximately $3,611,742.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ANGO. Gladius Capital Management LP purchased a new stake in AngioDynamics in the third quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of AngioDynamics by 37.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,105 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 2,491 shares in the last quarter. Quest Partners LLC bought a new position in shares of AngioDynamics in the 4th quarter worth about $69,000. RPO LLC purchased a new position in AngioDynamics during the 4th quarter valued at about $83,000. Finally, Dark Forest Capital Management LP bought a new stake in AngioDynamics during the third quarter worth about $85,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.